These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 27575715)

  • 1. CNS Target Identification and Validation: Avoiding the Valley of Death or Naive Optimism?
    Hutson PH; Clark JA; Cross AJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():171-187. PubMed ID: 27575715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of the use of transgenic animals in CNS drug discovery.
    Nestler EJ; Olivier B
    Curr Protoc Pharmacol; 2001 May; Chapter 5():Unit5.20. PubMed ID: 21965073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration.
    Brunner D; Balcı F; Ludvig EA
    Behav Processes; 2012 Feb; 89(2):187-95. PubMed ID: 22155361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The genetic and epigenetic landscape for CNS drug discovery targeting cross-diagnostic behavioral domains.
    de Mooij-van Malsen AJ; Pjetri E; Kas MJ
    Eur J Pharmacol; 2015 Apr; 753():135-9. PubMed ID: 25107283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanotechnology-based drug delivery for central nervous system disorders.
    Nguyen TT; Dung Nguyen TT; Vo TK; Tran NM; Nguyen MK; Van Vo T; Van Vo G
    Biomed Pharmacother; 2021 Nov; 143():112117. PubMed ID: 34479020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in the search for drugs to treat central nervous system disorders.
    Enna SJ; Williams M
    J Pharmacol Exp Ther; 2009 May; 329(2):404-11. PubMed ID: 19182069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges.
    Geerts H; Wikswo J; van der Graaf PH; Bai JPF; Gaiteri C; Bennett D; Swalley SE; Schuck E; Kaddurah-Daouk R; Tsaioun K; Pelleymounter M
    CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):5-20. PubMed ID: 31674729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tools in the Design of Therapeutic Drugs for CNS Disorders: An up-to-date Review.
    Sahu JK; Mishra AK
    Curr Mol Pharmacol; 2018; 11(4):270-278. PubMed ID: 30129422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Start small and stay small. Minimizing attrition in the clinic with a focus on CNS therapeutics.
    Nienaber V
    Curr Top Med Chem; 2009; 9(18):1688-704. PubMed ID: 19929834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CNS drug development - lost in translation?
    Talevi A; Bellera CL; Di Ianni M; Gantner M; Bruno-Blanch LE; Castro EA
    Mini Rev Med Chem; 2012 Sep; 12(10):959-70. PubMed ID: 22420574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Theoretical and practical applications of the intracerebroventricular route for CSF sampling and drug administration in CNS drug discovery research: a mini review.
    Kuo A; Smith MT
    J Neurosci Methods; 2014 Aug; 233():166-71. PubMed ID: 24937765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal drug delivery to the central nervous system: present status and future outlook.
    Tayebati SK; Nwankwo IE; Amenta F
    Curr Pharm Des; 2013; 19(3):510-26. PubMed ID: 23116337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNAs as CNS Drug Targets.
    Gurwitz D
    Drug Dev Res; 2016 Nov; 77(7):331-335. PubMed ID: 27569840
    [No Abstract]   [Full Text] [Related]  

  • 14. Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders.
    Conn PJ; Lindsley CW; Meiler J; Niswender CM
    Nat Rev Drug Discov; 2014 Sep; 13(9):692-708. PubMed ID: 25176435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifunctional drugs as neurotherapeutics.
    Van der Schyf CJ; Youdim MB
    Neurotherapeutics; 2009 Jan; 6(1):1-3. PubMed ID: 19110194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for Utilizing Neuroimaging Biomarkers in CNS Drug Discovery and Development: CINP/JSNP Working Group Report.
    Suhara T; Chaki S; Kimura H; Furusawa M; Matsumoto M; Ogura H; Negishi T; Saijo T; Higuchi M; Omura T; Watanabe R; Miyoshi S; Nakatani N; Yamamoto N; Liou SY; Takado Y; Maeda J; Okamoto Y; Okubo Y; Yamada M; Ito H; Walton NM; Yamawaki S
    Int J Neuropsychopharmacol; 2017 Apr; 20(4):285-294. PubMed ID: 28031269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bundling arrows: improving translational CNS drug development by integrated PK/PD-metabolomics.
    van den Brink WJ; Hankemeier T; van der Graaf PH; de Lange ECM
    Expert Opin Drug Discov; 2018 Jun; 13(6):539-550. PubMed ID: 29519169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Removing obstacles in neuroscience drug discovery: the future path for animal models.
    Markou A; Chiamulera C; Geyer MA; Tricklebank M; Steckler T
    Neuropsychopharmacology; 2009 Jan; 34(1):74-89. PubMed ID: 18830240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proceedings of the 2013 CINP summit: innovative partnerships to accelerate CNS drug discovery for improved patient care.
    Phillips AG; Hongaard-Andersen P; Moscicki RA; Sahakian B; Quirion R; Krishnan KR; Race T
    Int J Neuropsychopharmacol; 2014 Dec; 18(3):. PubMed ID: 25542690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opportunities and challenges in the discovery of new central nervous system drugs.
    Krause JE; Chenard BL
    Ann N Y Acad Sci; 2008 Nov; 1144():243-50. PubMed ID: 19076381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.